Market Cap 266.79M
Revenue (ttm) 70.84M
Net Income (ttm) -157.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -222.83%
Debt to Equity Ratio -0.48
Volume 669,000
Avg Vol 840,088
Day's Range N/A - N/A
Shares Out 99.18M
Stochastic %K 14%
Beta 1.92
Analysts Strong Sell
Price Target $8.20

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 653 02 00
Address:
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland
hechicero1131
hechicero1131 Jul. 30 at 7:28 PM
$ADCT This sucks, huge green candles offset by major price drops on <5000 shares
0 · Reply
JRobb66
JRobb66 Jul. 29 at 2:57 PM
$ADCT maybe somebody knows something… too big of a sloooow drop
1 · Reply
fort_worth_Jason
fort_worth_Jason Jul. 24 at 4:41 PM
$ADCT Hoping for some good news soon.
0 · Reply
vjtweet
vjtweet Jul. 23 at 3:19 PM
$ADCT starter position.. to add more above 3.3
0 · Reply
JRobb66
JRobb66 Jul. 23 at 8:48 AM
$ADCT FFS under $3?
0 · Reply
SwingGio
SwingGio Jul. 22 at 8:35 AM
$ADCT price compressing
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 20 at 7:26 PM
The attachment shows commercial-stage oncology focused bio shares trade @ meaningfully lower FY28 revenue multiples than non-oncology. Share prices are also lower YTD (as a peer group). We're merely sharing an observation. We're not suggesting oncology will catch up or otherwise fare batter in the future. The attachment shows all 37 comm'l-stage oncology focused bios (including 2 with PDUFAs) versus all 37 like non-oncology with market caps over $1.5B and all 37 with market caps of $160MM to $1.5B In the Tesaro fair value opinion (when acquired by GSK in 1/2019), Centerview Partners noted that oncology focused bios get roughly 8% better Year 3 multiples in M&A. Yes that was 6 years ago. We'd genuinely like to know if anyone can offer an explanation as to why oncology trades at lower FY2028 multiples than their non-oncology focused peers? $JAZZ $NVCR $SNDX $IOVA $ADCT
7 · Reply
SamHot
SamHot Jul. 16 at 7:18 PM
0 · Reply
SamHot
SamHot Jul. 16 at 7:15 PM
$ADCT Buy n Buy
0 · Reply
SamHot
SamHot Jul. 16 at 7:11 PM
$ADCT Time to buy more
0 · Reply
Latest News on ADCT
ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 7:15 AM EDT - 2 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences


ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:36 PM EDT - 2 months ago

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 11:17 AM EDT - 4 months ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 11:01 AM EST - 9 months ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript


ADC Therapeutics to Present at November Investor Conferences

Nov 4, 2024, 7:15 AM EST - 9 months ago

ADC Therapeutics to Present at November Investor Conferences


ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 9:26 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:04 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 1:24 PM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript


hechicero1131
hechicero1131 Jul. 30 at 7:28 PM
$ADCT This sucks, huge green candles offset by major price drops on <5000 shares
0 · Reply
JRobb66
JRobb66 Jul. 29 at 2:57 PM
$ADCT maybe somebody knows something… too big of a sloooow drop
1 · Reply
fort_worth_Jason
fort_worth_Jason Jul. 24 at 4:41 PM
$ADCT Hoping for some good news soon.
0 · Reply
vjtweet
vjtweet Jul. 23 at 3:19 PM
$ADCT starter position.. to add more above 3.3
0 · Reply
JRobb66
JRobb66 Jul. 23 at 8:48 AM
$ADCT FFS under $3?
0 · Reply
SwingGio
SwingGio Jul. 22 at 8:35 AM
$ADCT price compressing
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 20 at 7:26 PM
The attachment shows commercial-stage oncology focused bio shares trade @ meaningfully lower FY28 revenue multiples than non-oncology. Share prices are also lower YTD (as a peer group). We're merely sharing an observation. We're not suggesting oncology will catch up or otherwise fare batter in the future. The attachment shows all 37 comm'l-stage oncology focused bios (including 2 with PDUFAs) versus all 37 like non-oncology with market caps over $1.5B and all 37 with market caps of $160MM to $1.5B In the Tesaro fair value opinion (when acquired by GSK in 1/2019), Centerview Partners noted that oncology focused bios get roughly 8% better Year 3 multiples in M&A. Yes that was 6 years ago. We'd genuinely like to know if anyone can offer an explanation as to why oncology trades at lower FY2028 multiples than their non-oncology focused peers? $JAZZ $NVCR $SNDX $IOVA $ADCT
7 · Reply
SamHot
SamHot Jul. 16 at 7:18 PM
0 · Reply
SamHot
SamHot Jul. 16 at 7:15 PM
$ADCT Buy n Buy
0 · Reply
SamHot
SamHot Jul. 16 at 7:11 PM
$ADCT Time to buy more
0 · Reply
SamHot
SamHot Jul. 16 at 7:10 PM
0 · Reply
FavoredTrades
FavoredTrades Jul. 9 at 6:07 PM
$ADCT like this for weeks to come
0 · Reply
SwingGio
SwingGio Jul. 9 at 4:50 PM
$ADCT … 👏👏👏
0 · Reply
SwingGio
SwingGio Jul. 9 at 8:07 AM
$ADCT it's worth keeping an eye on …
0 · Reply
christopher18
christopher18 Jul. 8 at 5:26 PM
$ADCT I thought this would head back down to the $2S, but it seems to be holding this time around.
0 · Reply
christopher18
christopher18 Jul. 2 at 2:49 PM
$ADCT This appears to be holding up around the $2.75 mark and not going down much more from this price point.
0 · Reply
JRobb66
JRobb66 Jul. 2 at 9:29 AM
$ADCT ADC THERAPEUTICS SA 27,726,052 Common Shares Pursuant to this prospectus, the selling shareholders may offer an aggregate of 27,726,052 common shares from time to time if and to the extent as they may determine as described in the section entitled “Plan of Distribution” at prevailing market prices, at prices different than prevailing market prices or at privately negotiated prices. If any common shares are sold, the selling shareholders will pay any brokerage commissions and/or similar charges incurred for the sale of such shares. As required by the securities purchase agreements, dated June 11, 2025, with the selling shareholders, we are filing the registration statement of which this prospectus forms a part to permit the resale of 11,991,785 common shares and 15,734,267 common shares issuable upon exercise of the pre-funded warrants, in each case, issued and sold to the selling shareholders pursuant to such securities purchase agreements. We do not know whether,
0 · Reply
Atrain1189
Atrain1189 Jun. 26 at 1:53 PM
$ADCT question is, does this bleed on no news? Or moon because they literally raised $100 mil in shares 40% above current stock price
1 · Reply
SamHot
SamHot Jun. 25 at 11:01 AM
$ADCT Hold nothing under $12
0 · Reply
JRobb66
JRobb66 Jun. 24 at 11:27 AM
$ADCT can someone explain why it’s not $5 yet?
1 · Reply
Certifiedbagholder
Certifiedbagholder Jun. 24 at 3:51 AM
$ADCT glad I did stop losses at this temporary top. (still holding 20,000 shares) I have been using previous ADCT gains to day trade $SPY with its volatile week on my “play account”. It has been ABSOLUTELY incredible. When the time is right, all these gains are going right back to buy more ADCT.
1 · Reply
SamHot
SamHot Jun. 23 at 6:22 PM
$ADCT HOLD
0 · Reply